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A Synthesis of Current Surveillance Planning Methods for the Sequential
Monitoring of Drug and Vaccine Adverse Effects Using Electronic Health
Care Data
Abstract
Introduction: The large-scale assembly of electronic health care data combined with the use of sequential
monitoring has made proactive postmarket drug- and vaccine-safety surveillance possible. Although
sequential designs have been used extensively in randomized trials, less attention has been given to methods
for applying them in observational electronic health care database settings.
Existing Methods: We review current sequential-surveillance planning methods from randomized trials, and
the Vaccine Safety Datalink (VSD) and Mini-Sentinel Pilot projects—two national observational electronic
health care database safety monitoring programs.
Future Surveillance Planning: Based on this examination, we suggest three steps for future surveillance
planning in health care databases: (1) prespecify the sequential design and analysis plan, using available
feasibility data to reduce assumptions and minimize later changes to initial plans; (2) assess existing drug or
vaccine uptake, to determine if there is adequate information to proceed with surveillance, before conducting
more resource-intensive planning; and (3) statistically evaluate and clearly communicate the sequential
design with all those designing and interpreting the safety-surveillance results prior to implementation. Plans
should also be flexible enough to accommodate dynamic and often unpredictable changes to the database
information made by the health plans for administrative purposes.
Conclusions: This paper is intended to encourage dialogue about establishing a more systematic, scalable,
and transparent sequential design-planning process for medical-product safety-surveillance systems utilizing
observational electronic health care databases. Creating such a framework could yield improvements over
existing practices, such as designs with increased power to assess serious adverse events.
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Introduction: The large-scale assembly of electronic health care data combined with the use of 
sequential monitoring has made proactive postmarket drug- and vaccine-safety surveillance possible. 
Although sequential designs have been used extensively in randomized trials, less attention has been 
given to methods for applying them in observational electronic health care database settings.
Existing Methods: We review current sequential-surveillance planning methods from randomized trials, 
and the Vaccine Safety Datalink (VSD) and Mini-Sentinel Pilot projects—two national observational 
electronic health care database safety monitoring programs.
Future Surveillance Planning: Based on this examination, we suggest three steps for future  
surveillance planning in health care databases: (1) prespecify the sequential design and analysis plan, 
using available feasibility data to reduce assumptions and minimize later changes to initial plans; 
(2) assess existing drug or vaccine uptake, to determine if there is adequate information to proceed 
with surveillance, before conducting more resource-intensive planning; and (3) statistically evaluate 
and clearly communicate the sequential design with all those designing and interpreting the safety-
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dynamic and often unpredictable changes to the database information made by the health plans for 
administrative purposes.
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Introduction
New Safety Systems Using Electronic Data
Improving methods to monitor the safety of vaccines 
and drugs following United States Food and Drug 
Administration (FDA) approval is a crucial public 
health need.1 Postmarket safety monitoring relies on 
passive surveillance from voluntary reports—from 
manufacturers, patients, and health care providers—
of adverse effects suspected to be associated with a 
specific drug or vaccine.2-3 Now, with the purposeful 
assembly of “big data” resources for public health 
research and surveillance, such as electronic health 
records and claims data maintained by health plans 
and insurers for administrative and clinical purposes, 
proactive safety surveillance is possible and can 
supplement passive surveillance. The Vaccine Safety 
Datalink (VSD)4 and the Mini-Sentinel Pilot project 
to establish the Sentinel system5-6 are two notable 
examples of national networks that are leveraging 
vast amounts of health care database information 
to conduct safety surveillance for marketed medical 
products. The VSD was created in 1990 by the 
Centers for Disease Control and Prevention (CDC) 
to study the adverse effects of vaccines and has 
involved collaboration with 10 health care systems. 
Sentinel is an electronic surveillance system that 
involves about 20 participating institutions and was 
initiated by the FDA in 2008 to monitor the safety of 
all FDA-regulated medical products.
Active Surveillance Using Sequential Monitoring
One approach used in these systems to assess safety 
is sequential monitoring, which permits repeated 
estimation and testing of associations between a 
new drug or vaccine and potential adverse events 
over time.7-19 Compared to a traditional design with a 
single analysis or test at the study’s end, a sequential 
analysis computes the test statistic at periodic time 
intervals as data accumulate, compares this test 
statistic to a prespecified signaling threshold, and 
stops if the observed test statistic is more extreme 
than the threshold. In this way, sequential tests can 
facilitate earlier identification of safety signals as 
soon as sufficient information from the electronic 
health care database becomes available to detect 
elevated adverse event risks. While sequential 
methods have been used extensively in randomized 
trials,20 using them to monitor safety in a multisite, 
observational electronic health care database 
setting raises new challenges:21-22 (1) analyzing rare 
adverse events; (2) controlling for confounding 
and channeling; (3) accommodating dynamic 
database updating by health plans over time, and 
the unpredictable uptake of newly approved medical 
products. (Note: These challenges also apply more 
Conclusions: This paper is intended to encourage dialogue about establishing a more systematic, 
scalable, and transparent sequential design-planning process for medical-product safety-surveillance 
systems utilizing observational electronic health care databases. Creating such a framework could  
yield improvements over existing practices, such as designs with increased power to assess serious 
adverse events.
CONTINUED
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generally to traditional onetime safety assessments 
in this setting, but we focus here on sequential 
applications of these methods.) Consequently, many 
new sequential methods have emerged that (1) use 
exact test methods tailored for rare events, (2) offer 
a variety of confounder adjustment strategies, (3) 
can robustly handle real-time changes in the data, 
and (4) can accommodate unexpected patterns of 
new product uptake.23 Approaches have included 
historically controlled or single arm designs,16,24-25 
self-controlled designs,24,26 exposure matching,24 
stratification on categorical confounders,27 as well 
as adjustment for confounding at the analysis 
phase through regression28 or inverse probability 
weighting.29
Sequential Design Considerations
In addition to the standard design steps that are 
typically undertaken for a traditional epidemiological 
study with a single analysis at the study’s end, 
planning for sequential safety surveillance involves 
additional considerations: (1) When should 
surveillance start and end? (2) How frequently 
should interim tests be performed? (3) What 
should the statistical threshold be for a safety 
signal, and should it change over time? Answers 
to these questions define the statistical properties 
of the study design (e.g., Type 1 error, power, and 
expected time until signal detection). Frameworks 
to address these questions in randomized trials are 
well established, and decisions are typically guided 
by the trial’s scientific goals, ethical concerns, and 
practical circumstances.30 Less consideration has 
been given to sequential design selection steps 
in an observational setting using electronic health 
care data sources, where the safety questions, 
consequences of confirming a signal, and costs of 
false positive and negative errors differ. In particular, 
a safety signal generated from observational 
surveillance using electronic data is a preliminary 
finding that requires considerable follow-up 
investigation. The level of evidence generated from a 
randomized trial is stronger and could more quickly 
lead to regulatory action.
In this paper, we describe current methods for 
planning sequential monitoring activities, including 
prevailing guidance for randomized trials. We also 
summarize examples of sequential surveillance 
planning steps from the VSD project and Mini-
Sentinel pilot. We identify the strengths as well as 
opportunities to improve upon existing approaches, 
focusing on sequential design selection and sample 
size planning in these examples. Last, we provide 
suggestions for future sequential design planning 
and illustrate the proposed steps using an example 
of a drug with a known adverse effect: angiotensin-
converting enzyme (ACE) inhibitors and the risk of 
angioedema.31 The ultimate goal of this work is to 
further the dialogue about establishing a systematic 
sequential surveillance planning process for use 
within observational electronic health care database 
settings, both within government agencies that 
monitor the safety of regulated medical products 
(e.g., FDA and the CDC) and between those 
agencies and external scientists who conduct safety 
evaluations and research studies. Creating such a 
framework could yield important improvements over 
existing practices, such as designs with increased 
power to assess serious adverse events.
Existing Safety Surveillance Planning 
Practices
Guidance from Randomized Clinical Trials
The use of sequential designs to monitor 
randomized clinical trials is common practice and 
has been well described.20 Thus, we do not provide 
a comprehensive review here but rather highlight 
selected statistical recommendations that reflect 
the current state-of-the-art in practice. For example, 
the FDA provides extensive guidance on statistical 
principles for clinical trials conducted by industry, 
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many of which involve group sequential interim 
monitoring.32 In addition, a set of minimum standards 
for adaptive randomized clinical trials has been 
recently developed for comparative effectiveness 
research conducted within the Patient-Centered 
Outcome Research Institute.33 Table 1 summarizes 
key recommendations from both these sources 
and their potential relevance in an observational 
safety setting using electronic data like the VSD and 
Sentinel.
Experience from the Vaccine Safety Datalink (VSD) 
Collaboration
Continuous Sequential Testing Methods
Sequential designs, employing either continuous 
or group sequential testing, have also been 
developed for and implemented in the VSD’s 
observational database surveillance setting. Table 
2 summarizes the main features of these designs. 
After preliminary exploration with the original 
sequential probability ratio test (SPRT),34 initial 
sequential safety-surveillance efforts within the VSD 
utilized the maximized sequential probability ratio 
test (MaxSPRT) method.24 This approach involves 
near-continuous sequential monitoring and uses 
a one-sided likelihood ratio test (LRT) that rejects 
the null hypothesis of no difference in the risk of a 
prespecified adverse event between a vaccine of 
interest and comparator if the log likelihood ratio 
(LLR) exceeds a constant upper value. In other 
words, MaxSPRT uses a constant (or flat) signaling 
boundary over time on the scale of the LLR.
Surveillance using MaxSPRT has typically been 
conducted for a small number of prespecified 
outcomes (about 5 to 10) for a specific duration of 
calendar time, such as two or three years following 
introduction of a new vaccine7-12 or, in the case 
of influenza vaccine monitoring, for the duration 
of influenza season.13-14 This is in contrast to a 
monitoring approach that follows vaccine recipients 
until a specific sample-size requirement designed 
to achieve a desired level of statistical power is met 
(i.e., one that uses information time to determine the 
surveillance duration). In some instances, statistical 
power was computed post hoc after surveillance 
was completed.35
Continuous sequential testing (versus group 
sequential testing) is advantageous because, on 
average, it can identify true safety signals sooner. 
However, continuous testing may not be feasible 
within a large, multisite system if the data are 
not updated in a real-time, continuous fashion. 
In addition, continuous testing is inherently less 
powerful than designs with less frequent testing 
given a fixed sample size.36 This is because more 
frequent testing increases the overall chances of a 
false signal or Type 1 error, and thus the signaling 
threshold must be increased to avoid this problem. A 
flat boundary can also enhance early identification of 
signals, as it imposes a lower, less conservative signal 
threshold at early tests. But, by not employing early 
conservatism, use of a flat boundary can lead to false 
positive signals based on relatively little information 
at early analyses. This problem was observed in 
several VSD studies37 and led to the development 
of continuous methods that implement a “delayed 
start,” postponing the first test until a specified 
minimum number of events has been observed.38 
Further technical details on the advantages and 
limitations of continuous, compared with group, 
sequential testing methods in a postlicensure safety 
setting are beyond the scope of this manuscript but 
have been described elsewhere.21,36,39-40
Group Sequential Testing Methods
Group sequential methods were first adapted from 
clinical trials for use in an observational safety 
setting using electronic data in a VSD study of a new 
pentavalent combination vaccine for infants (trade 
name: Pentacel).16 Similar to prior VSD studies, the 
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Table 1. FDA32 and PCORI33 Recommendations on Sequential Testing in Clinical Trials and Their 
Relevance to Observational Electronic Health Care Database Safety Surveillance Settings like Sentinel
RECOMMENDATION DESCRIPTION
RELEVANT FOR OBSERVATIONAL 
SURVEILLANCE?
Prespecify statistical 
design and primary 
analysis and document 
changes.
All statistical methods should be prespecified 
prior to obtaining information on treatment 
outcomes, including the schedule of interim 
analyses, stopping rules and their properties, 
primary hypotheses, underlying statistical 
model, use of one- versus two-sided tests, 
and designation of primary versus exploratory 
analyses. It is important to document protocol 
deviations as changes made to the original plans 
can weaken and even invalidate the results.
Yes. It is equally important in observational 
settings to prespecify analytic plans to the extent 
possible. However, observational surveillance is 
subject to many more unknowns and may need to 
flexibly accommodate some changes when plans 
cannot be implemented as initially expected. Such 
changes should be documented and explained so 
that appropriate interpretations may be made.
Evaluate statistical 
properties of the design 
in advance.
The statistical properties of the design should be 
evaluated a priori so that they are understood 
prior to implementation and in the context of 
the research question (e.g., adequate power for 
several assumed treatment effects). For complex 
designs, this might include evaluating properties 
over a range of assumptions relating to size of 
treatment effect, missing data, dropout rates, 
etc. Technical details should be included in an 
appendix (e.g., statistical models and significance 
thresholds for the primary analyses along with 
calculation details or software used, operating 
characteristics for the design along with methods 
and assumptions for computing them).
Yes. But it may not be as desirable or practical to 
conduct an extensive performance evaluation for 
surveillance applications because of the following: 
(1) Surveillance may be done for many exposure-
outcome pairs at once, making it less feasible to 
conduct an extensive evaluation for each design, 
and (2) many unknowns can lead to changes in 
the actual versus designed implementation, which 
may downweight the need to understand the 
planned design’s performance in depth. It also 
may be helpful to use relatively simple designs 
that are well understood, can be reused, and can 
be scaled up. 
Communicate and vet the 
design in advance.
The sequential design and analyses should be 
clearly communicated and vetted with those 
designing and interpreting the safety surveillance 
activity to assess acceptability to address the 
primary aims.
Yes. It is important that those designing and 
interpreting the safety surveillance activity (e.g., 
FDA) understand how the design will work in 
practice so any potential actions taken based on a 
safety signal are suitable.
Account for multiple 
testing.
The chance of making a Type 1 error will  
increase due to testing multiple outcomes, 
treatment comparisons, subgroups, or repeated 
analyses over time and should be addressed, 
potentially using frequentist Type 1 error 
adjustment methods.
Yes. However, the importance of strict accounting 
for random variation via multiple testing may be 
less in an observational surveillance setting since 
systematic variation will be (relatively) larger and 
sample sizes relatively larger. It is likely worth 
adjusting for sequential tests across multiple 
analysis time points, but it may be less necessary 
to adjust across multiple outcomes (since very 
few outcome are targeted for surveillance) or 
subgroups (since this is already designated as 
exploratory). 
Interpret exploratory 
analyses with caution.
Exploratory analyses (e.g., in subgroups) should 
be interpreted with caution and should generally 
not be used to make definitive conclusions 
regarding treatment effects.
Yes. In general, surveillance results are more 
exploratory than results from trials. However, 
when prespecified, surveillance may reasonably 
test specific hypotheses. Results of surveillance 
analyses that are not prespecified should be 
considered as hypotheses for further evaluation.
Ensure proper oversight 
and reporting.
Proper statistical oversight of trial conduct should 
be in place, and reporting of the results should be 
done in a consistent fashion.
Yes. Statistical oversight and reliable reporting 
are key components for surveillance, given the 
data and analysis complexities and the desire for 
transparent presentation.
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Table 2. Key Features of the Planned Sequential Designs Used in the VSD Collaboration and MS Pilot
SEQUENTIAL 
DESIGN 
FEATURES
CONTINUOUS 
TESTING: 
SEVERAL VSD 
STUDIES
GROUP SEQUENTIAL 
TESTING: VSD 
PENTACEL SAFETY 
STUDY16 
(SEPT. 2008– 
JAN. 2011)
GROUP 
SEQUENTIAL 
TESTING: VSD 
PCV13 SAFETY 
STUDY15 
(APR. 2010– 
JAN. 2012)
GROUP 
SEQUENTIAL 
TESTING: 
SAXAGLIPTIN 
EVALUATION IN 
MS17 
(AUG. 2009– 
JAN. 2014)
GROUP 
SEQUENTIAL 
TESTING: 
RIVAROXABAN 
EVALUATION IN 
MS18 
(NOV. 2011– 
APR. 2015)
Surveillance  
start
As soon as 
uptake begins 
or delayed until 
a preset # of 
events occur
Delayed start until 1 
year of uptake (for early 
conservatism)
Specified in doses 
(information time) 
based on power for 
specific RRs
Specified in new 
users (information 
time) based on 
power for specific 
HRs
Specified in new 
users (information 
time) based on 
power for specific 
HRs
Surveillance  
end
Specified in 
calendar time 
~2–3 years after 
the first dose
Specified in doses 
(information time) based 
on power for specific 
RRs; varied by event 
prevalence (N=72,000 
doses if common, 
150,000 if rare)
Specified in 
information time 
based on power to 
detect specific RRs; 
varied by adverse 
event prevalence
Specified in 
information time 
and based on 
power to detect 
specific HRs; 
resulted in last 
analysis ~6 years 
after licensure
Specified in 
information time 
and based on 
power to detect 
specific HRs 
Frequency  
of testing
Specified in 
calendar time 
as weekly
12 total tests based 
on doses (information 
time); spacing between 
analyses depended on 
event prevalence: 3,500 
or 10,500 doses
12 total tests based 
on information time; 
spacing depended 
on event prevalence
7 total tests, 
planned to be 
equally spaced 
based on 
information time 
5 total tests, 
planned based on 
information time to 
occur at 35, 47, 62, 
80, and 100% of 
the total person-
time 
Duration of 
surveillance
Specified in 
calendar time 
as 2–3 years
Specified in information 
time; resulted in ~2.5 
years
Specified in 
information time; 
resulted in ~2 years
Specified in 
information time; 
resulted in ~6 
years
Specified in 
information time
Shape of 
signaling 
threshold over 
time
Constant (flat) 
threshold on 
the scale of the 
LRT statistic
Constant (flat) threshold 
on the scale of the LRT 
statistic
O’Brien-Fleming 
threshold on the 
LRT scale, which 
is higher at earlier 
analyses
Constant (flat) 
threshold on the 
scale of the Wald 
statistic
Constant (flat) 
threshold on the 
scale of the Wald 
statistic
Test statistic LRT LRT LRT Wald Wald
Test type one-sided one-sided one-sided one-sided two-sided
Adjust 
thresholds?
No Yes No No No
Apply data lag 
so data are 
more complete?
2–3 months 2–3 months 2–3 months Varied by Data 
Partner (some lag 
by 6–9 months, 
others do not lag)
Varied by Data 
Partner (some lag 
by 6–9 months, 
others do not lag)
Freeze prior 
data?
Freeze results 
from prior 
analyses and 
add only new 
information.
Primary: Cumulatively 
refresh all data since 
start of surveillance at 
each interim analysis. 
Secondary: Freeze 
results from prior 
analyses and add only 
new data.
Cumulatively refresh 
all data since start 
of surveillance at 
each new interim 
analysis
Cumulatively 
refresh all data 
since start of 
surveillance 
but preserve 
matches from 
prior analyses 
whenever feasible.
Cumulatively 
refresh data 
since start of 
surveillance.
6
eGEMs (Generating Evidence & Methods to improve patient outcomes), Vol. 4 [2016], Iss. 1, Art. 17
http://repository.edm-forum.org/egems/vol4/iss1/17
DOI: 10.13063/2327-9214.1219
Volume 4 (2016) Issue Number 1
Pentacel safety study used a one-sided LRT with 
a flat signaling boundary to test whether the risk 
of several targeted adverse events was elevated 
among Pentacel recipients versus comparators. 
Instead of continuous testing, however, 12 group 
sequential interim tests were planned. The first test, 
which occurred after one year of Pentacel uptake 
(N=33,308 doses), was purposely delayed to apply 
early conservatism and minimize early false positive 
signaling. Subsequent tests were planned to be 
equally spaced, based on the number of newly 
accruing Pentacel vaccine recipients needed to 
achieve specific statistical power goals. In other 
words, the spacing between interim analyses was 
based on the number of new Pentacel doses (i.e., 
information time) as opposed to a preset number of 
weeks or months (i.e., calendar time).
Given this sequential design and the expected 
adverse event rate among comparators, the 
maximum total sample size required to achieve at 
least 80 percent power to detect a specific minimum 
relative risk of interest for each outcome was 
computed. For more common events, this resulted 
in tests being performed after each additional batch 
of 3,500 doses of Pentacel was observed, up to a 
maximum sample size of about 72,000 doses. For 
rarer events, tests were planned to occur after each 
new 10,500 doses accrued among VSD enrollees, 
with a maximum sample size of about 150,000 
doses. In addition to prespecified adverse events, 
a nonspecific severe outcome (e.g., any-cause 
hospitalization) and several control outcomes were 
analyzed as end-of-study, nonsequential endpoints.
In settings like the VSD and Sentinel, where data 
are captured and dynamically updated over time 
by health care organizations for administrative and 
clinical purposes, many unanticipated changes to the 
data can occur for newly approved products during 
the surveillance period. These unpredictable factors 
can constrain the ability to conduct sequential 
analyses exactly according to a prespecified plan. 
Complications that arose in the Pentacel study 
included the following:
1. There was unanticipated differential uptake of 
vaccine by age and by data partner.
2. Each planned interim analysis could not be 
performed at exactly the number of doses 
that was prespecified because data were not 
refreshed continuously but rather in discrete 
weekly batches. For instance, the second analysis 
was planned to occur at 36,808 doses. However, 
it was conducted at 37,851 doses in week 59 of 
surveillance because fewer than the required 
36,808 doses were available at week 58 and 
more than 36,808 had accrued by week 59.
3. Due to an unforeseen data quality issue that was 
identified and later corrected, an unexpectedly 
large amount of previously missing Pentacel 
vaccine data was updated at a single time point 
from one data partner.
This lack of experimental control affects the adverse 
event variability and, in turn, the probability of 
committing a Type 1 error that investigators want to 
control. To account for these unpredictable changes 
in the data and still maintain proper error control 
in the Pentacel analysis, the planned sequential 
thresholds were modestly adjusted at each analysis 
to reflect the actual (versus planned) way in which 
the data were analyzed.16 Since actual departures 
from the planned analyses were small, threshold 
adjustments were correspondingly small.
Tseng et al. also used a group sequential approach to 
monitor 13-valent pneumococcal conjugate vaccine 
(PCV13) safety in children in the VSD.15 As in the 
Pentacel vaccine study, actual conduct of the PCV13 
safety study was modestly different than initially 
planned.15 In particular, investigators planned to finish 
surveillance for all prespecified outcomes within two 
years. However, accrual of information for the rarest 
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events did not occur quickly enough to meet this 
goal. Thus, some testing plans needed modification. 
Table 2 provides more detail on the selected 
sequential features of this study. Note that the final 
two rows of Table 2 address two technical data-
related questions that sequential surveillance plans 
have faced in the VSD. First, should investigators 
impose a data lag to improve completeness? In other 
words, instead of including all data captured in the 
databases up to the day before each interim analysis 
is conducted, should investigators wait several weeks 
or months before including a patient’s data in an 
analysis? This would increase the probability that 
all relevant information (i.e., on vaccine exposure, 
adverse events, and confounders) has been correctly 
and completely captured in the database. Second, 
at each interim analysis when data are cumulatively 
examined since the surveillance start, how should 
prior data be treated? Should the previously 
analyzed data be frozen and only new data be 
appended that have been captured since the prior 
analysis? Or, should all the information observed 
since the beginning of the study be cumulatively 
refreshed?
With regard to data lagging, the standard practice 
within the VSD has been to simply lag the incoming 
data for analysis by about two to three months. For 
instance, if an analysis were conducted on March 
1, the most recent health encounter data included 
would be those observed through January 1. This lag 
period has been instituted because some relevant 
vaccine and adverse event information is known not 
to be captured in the databases instantaneously, 
for example, due to relatively slower-arriving claims 
data when enrollees are seen at hospitals outside 
the integrated health system data partner. The 
rationale for waiting two to three months is that 
VSD data have been shown to stabilize and become 
much more complete after this period, which 
improves the validity of the results.35 With respect to 
freezing prior data, the approach has varied by VSD 
study, depending on specific design and method 
considerations. In some cases, multiple approaches 
were used to assess the impact of different 
strategies on the final results.16
Ongoing Safety Assessments in Mini-Sentinel
A small number of sequential safety evaluations for 
drugs17-18 and vaccines19 have been conducted within 
Mini-Sentinel. Many of the lessons learned from 
sequential safety studies conducted within the VSD 
have been applied when planning these surveillance 
activities. Table 2 summarizes the key features of 
these designs. Since Mini-Sentinel data are updated 
on an approximately quarterly schedule, rather than 
near-continuously as in the VSD, group sequential 
designs have been the primary method utilized 
within Mini-Sentinel thus far.
As described for the VSD studies in the previous 
section, the actual sequential conduct of pilot 
Mini-Sentinel evaluations was not always the 
same as specified in initial plans, particularly for 
new products. For instance, in the rivaroxaban 
surveillance activity,18 sample sizes were estimated 
for various potential scenarios of interest that 
varied the minimum hazard ratios (HRs) of interest 
detectable with 80 percent power. Calculations 
assumed that five group sequential analyses would 
be conducted based on information time when 
35, 47, 62, 80, and 100 percent of new users were 
observed. Based on these calculations, the maximum 
sample size required to achieve 80 percent power 
to detect the smallest desired HR of 1.5 for the least 
common outcome of intracranial hemorrhage was 
estimated to be about 16,000 new rivaroxaban 
users. (Note: The maximum sample size is defined 
to be the sample size at the fifth and final planned 
analysis if no safety signal is detected.) In practice, 
largely because this was a first-of-its-kind pilot 
activity for drug surveillance within the Mini-Sentinel 
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environment, the actual timing of sequential tests 
was conducted when it was feasible based on 
operational factors. Specifically, the first test was 
conducted as soon as possible in calendar time after 
the surveillance plan was finalized, after about 15,000 
new rivaroxaban users had been observed. Thus, 
by the time of the first analysis, the sample size was 
already almost as large as the estimated maximum 
sample size. In other situations, slower-than-
expected new drug uptake may occur, yielding the 
opposite situation. Both circumstances highlight the 
challenge of aligning sequential design plans (which 
may be based on information time spacing between 
interim analyses so that power considerations are 
well understood) and the actual implementation of 
these analyses (which may be driven by practical 
calendar time and logistical constraints).
Summarizing the Lessons Learned from Prior 
Sequential Evaluations
Many of the established planning practices for 
randomized trials can help increase the integrity of 
a sequential safety evaluation in an observational, 
electronic health care–database surveillance setting. 
However, the extent to which each recommendation 
applies may vary due to practical and scientific 
differences from the clinical trial setting and 
population. Table 1 highlights the relevance of 
recommendations from clinical trials to safety 
surveillance settings. The sequential vaccine-safety 
surveillance experience within the VSD and the pilot 
surveillance activities conducted within Mini-Sentinel 
offer further lessons that should be considered when 
planning future surveillance activities. Key among 
these are the following:
1. Collect and use preliminary data to inform 
planning. This can reduce the number of 
assumptions that need to be made at the 
planning phase and, in turn, can minimize 
downstream changes to initial sequential plans. 
For instance, assessing the amount of existing 
new drug or vaccine use prior to developing the 
surveillance plan can better facilitate sample-
size estimation and provide insight into how 
quickly in calendar time sample-size needs may 
be achieved. Examining the distribution of key 
potential confounders in the population of interest 
and computing background rates of adverse 
events among the likely comparator group can 
also help refine sample-size calculations.
2. Provide an opportunity for preliminary discussion
with those designing and interpreting the safety 
surveillance activity. Clear communication in 
advance of a sequential design’s operating 
characteristics and joint selection of the final 
design with those designing and interpreting 
the safety surveillance activity is essential. Then, 
the definition of a safety signal, which depends 
on the selected sequential design’s signaling 
thresholds over time, will be well understood and 
will be better aligned with the follow-up actions 
that may be taken should a signal occur.
3. Employ early conservatism at the surveillance 
start. Using a design with a delayed start (as in 
the VSD Pentacel safety study16) or with a higher 
boundary at early versus later analyses (as in the 
VSD PCV13 safety study15) can help reduce false 
positive signals based on relatively little data at 
early analyses.
4. Conduct a traditional sample-size calculation. 
This can help facilitate an understanding of 
how much information is needed to address a 
particular safety question, ensure that there is an 
adequate amount of new data between interim 
analyses to warrant performing a new data 
analysis, and better estimate how long it will be 
necessary to conduct surveillance.
5. Prepare to accommodate dynamically changing 
health plan data and prescribing patterns. 
Implementing sequential analyses in an 
unpredictable, observational electronic health 
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care–data setting needs flexibility and caution. 
Even with informed and well-vetted planning steps 
in place, the precise rate of new drug or vaccine 
uptake, the population composition of new users, 
and the timing of database updates by health 
plans are not known in advance. Thus, investigators 
need to be prepared to adjust initial plans based on 
actual uptake, acceptance, and other constraints.
Since post hoc changes to initial plans can potentially 
introduce bias, any resulting modifications to 
initial surveillance plans should be justified and 
well documented. In addition, implementing a 
time lag between when data are first captured by 
a data partner and when they are included in an 
analysis is important to increase data accuracy 
and completeness and to reduce instability that 
may be caused by health plan data updates. The 
ability to make these informed adjustments when 
unexpected changes occur in the data, and the ability 
to successfully implement data lagging strategies 
to reduce bias, inherently require an in-depth, local 
understanding of the data from each contributing 
data partner. The value of having and utilizing this local 
data knowledge in this way cannot be overstated.
Applying Prior Lessons to Future 
Surveillance Planning
Potential Improvements to Future Safety Evaluations 
Using Observational Electronic Health Data
In this section, we translate these lessons learned 
from prior studies into concrete, sequential design-
planning steps that could be used to improve future 
safety evaluations in observational, electronic health 
care–database settings, either for a onetime analysis 
or multiple sequential analyses over time. We 
illustrate these steps using an example of a product-
outcome pair where there is a known adverse effect: 
ACE inhibitors and risk of angioedema.31 The goal 
is to design a set of steps that meet the following 
criteria: (1) simple, so planning can be rapid, efficient, 
and scalable; (2) interpretable, so the steps are easy 
to understand and repeatable, (3) transparent, so 
planning decisions can be easily shared with those 
designing and interpreting the safety surveillance 
activity; and (4) scientifically sound, to ensure 
rigorous surveillance that leads to maximal public 
health benefit. The proposed steps are as follows:
1. Use available data (or existing literature) to 
conduct a feasibility assessment and prespecify 
the surveillance plan. This can provide a rough 
estimate of the overall sample size needed 
to address the designated safety question of 
interest in the target population.
2. Describe uptake for the product of interest to 
determine whether or not there is adequate 
uptake to meet these sample-size needs and 
thus to move forward with additional surveillance 
planning activities for either a onetime or a 
sequential analysis.
3. Statistically evaluate, jointly select, and clearly 
FRPPXQLFDWHWKHŚQDOVHTXHQWLDOGHVLJQ with 
those designing and interpreting the safety 
surveillance activity. To conserve resources, 
this more time-intensive planning step, which 
includes finalizing the sample-size requirements, 
should occur only after enough product use has 
been observed. To cope with the dynamically 
changing data, investigators should plan for 
some flexibility in implementing the design and 
documenting any changes to initial plans.
Step 1: Feasibility Assessment
Step 1 can occur as soon as a product has been 
identified as being a priority for surveillance. This 
feasibility assessment should be informed by existing 
data (e.g., data from the same sources or a subset 
of the same sources that will be used in the actual 
surveillance activity) and should roughly estimate 
the sample size needed to address the prespecified 
safety questions based on background rates 
10
eGEMs (Generating Evidence & Methods to improve patient outcomes), Vol. 4 [2016], Iss. 1, Art. 17
http://repository.edm-forum.org/egems/vol4/iss1/17
DOI: 10.13063/2327-9214.1219
Volume 4 (2016) Issue Number 1
estimated in the comparator group. Specifically, 
one can estimate required sample sizes to detect a 
minimum relative risk or risk difference of interest 
both for a onetime analysis and for a very basic 
sequential design (e.g., with four or eight total tests 
equally spaced based in information-time, a flat 
signaling threshold over time, one-sided test, 90 
percent power, and 5 percent Type 1 error), varying 
the prevalence of exposure over a plausible range.
Table 3 (see top half) displays this type of preliminary 
data for a logistic regression analysis of the 
association between ACE inhibitors and the risk 
of angioedema within 30 days of exposure. For 
example, if 25 percent of the study population uses 
ACE inhibitors and a relative risk of 2 is of interest to 
detect, then them a study cohort of 308,745 total 
users (ACE inhibitors and comparators combined) is 
needed for a onetime assessment with 90 percent 
power, assuming an estimated outcome rate of 3.08 
events per 10,000 person-months. Larger sample 
sizes are needed if multiple analyses are performed, 
but the increment in sample size required decreases 
as the number of additional sequential tests increases 
(371,041 for 4 analyses, 394,857 for 8 analyses, and 
415,189 for 16 analyses). Table 3 (see bottom half) 
presents this same information for a linear regression 
analysis designed to estimate a risk difference. 
Considerably smaller sample sizes are needed to 
detect comparable signals on the risk difference scale 
since the risk difference is more stable than a relative 
difference measure when events are rare. Selection 
of the relative risk (or risk difference) that surveillance 
should aim to detect should be based on the risk-
benefit profile of the new drug and, in particular, 
what safety signal threshold value is meaningful to 
regulators and should thus raise an alert.
Step 2: Uptake of the Medical Product
Once the approximate sample size is estimated, 
those requirements should be compared with the 
actual product uptake observed in the database 
(Step 2). This descriptive uptake assessment can 
help guide decisions about whether a well-powered 
onetime analysis can address the safety surveillance 
question, whether there are not enough users for 
a onetime analysis but there is adequate uptake to 
initiate routine sequential surveillance, or whether 
continued uptake monitoring is needed. For an 
existing medical product that has been on the market 
for many years, there may already be an adequate 
number of users to allow a single, well-powered 
analysis. For newer products, there may be too 
few users for a onetime analysis, but there may be 
enough to support the initiation of routine sequential 
surveillance. For other new products, uptake may be 
very slow, and continued uptake monitoring may be 
needed before any further planning is worthwhile. 
Although continued product uptake is generally 
expected, this may not always be the case.
Step 3: Performance Characteristics of the Final 
Design
As soon as the observed uptake numbers (from 
Step 2) reach the estimated preliminary sample-size 
needs (from Step 1) either for a onetime analysis 
or for initiation of a sequential evaluation, one can 
finalize the surveillance plan (Step 3). Because this 
third step involves more extensive planning, it should 
occur only once it is evident that uptake is adequate 
to conduct an evaluation. The goal of this step is to 
examine the properties of several potential designs 
in more detail so that they are fully understood prior 
to implementation. This process should involve clear 
communication and collaborative vetting of several 
potentially suitable sequential-surveillance designs 
with those designing and interpreting the safety 
surveillance activity in order to assess acceptability 
of that design in addressing the primary safety aims. 
Choices include the number and timing of analyses as 
well as the shape of the signaling boundary over time. 
Once the final design is selected, then final estimated 
sample-size requirements can be computed for that 
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Notes: *Assumptions: Binary outcome: Angioedema in 30 days after exposure; Comparator group: Beta blockers; Estimated rate of 
outcome among comparator group: 3.08/10,000 person-months; Boundary shape: Flat on standardized Z-statistic scale; Power: 90% 
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quired to achieve 90% power to detect a specified minimum RR or RD of interest if no signal is detected during the course of a sequential 
evaluation.
Table 3. Maximum Sample Size for Logistic Regression Analysis By Number Of Analyses
LOGISTIC REGRESSION TO ESTIMATE A RELATIVE RISK (RR)
  MAXIMUM SAMPLE SIZES
% of total sample 
who are ACE users RR 1-TIME 4-TIMES 8-TIMES 16-TIMES
25% 1.5 902,285 1,084,340 1,153,941 1,213,358
2 308,745 371,041 394,857 415,189
3 122,903 147,701 157,182 165,275
50% 1.5 676,714 813,255 865,456 910,019
2 231,559 278,281 296,143 311,392
3 92,178 110,776 117,887 123,957
LINEAR REGRESSION TO ESTIMATE A RISK DIFFERENCE (RD)
 MAXIMUM SAMPLE SIZES
% of total sample 
who are ACE users RD 1-TIME 4-TIMES 8-TIMES 16-TIMES
25% 1.5 625,032 751,145 799,360 840,519
3 156,258 187,787 199,840 210,130
6 39,065 46,947 49,960 52,533
50% 1.5 468,774 563,359 599,520 630,389
3 117,194 140,840 149,880 157,598
6 29,299 35,210 37,470 39,400
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design, which will ultimately determine how long 
surveillance needs to be conducted.
Table 4 displays the type of detailed data that 
are useful for making sequential design decisions. 
Specifically, sample-size estimates are shown for 
a wide variety of potential sequential designs 
that implement a logistic regression analysis to 
estimate the relationship between ACE inhibitors 
and the occurrence of angioedema within 30 days 
of exposure. Both the number of total planned 
analyses and the shape of the signaling threshold 
over time are varied across a range of values for 
exposure uptake and minimum detectable relative 
risks (RRs) of interest. Several common sequential-
threshold options are shown, including a Pocock 
signaling threshold that is constant over time on the 
scale of the test statistic (a Z-score),41 a curvilinear 
O’Brien-Fleming threshold that is highest at the first 
few analyses to achieve early conservatism,42 and a 
power family threshold that lies “in between” these 
two extremes.43-44 Figures 1–2 show the magnitude 
of the signaling thresholds on the test statistic 
(Z-score) scale as well as the more interpretable RR 
scale for selected designs.
For instance, based on Figure 1, a sequential design 
with only 4 analyses would result in the first analysis 
not being conducted until about 80,000-90,000 
new users have been observed for any design. This 
may be viewed as waiting too long if there truly is 
increased harm. Focus might then turn to designs 
with more frequent analyses, such as those with 8 or 
16 total planned analyses presented in Table 4 and 
Figure 2. At the first analysis, all designs with 16 total 
tests could signal after about 5 adverse events are 
observed in the comparator group (see Analysis 1, 
bottom of Figure 2). This number of events may be 
deemed too small a number upon which to base a 
preliminary safety signal, and that may direct further 
attention to the designs with 8 analyses. The designs 
with 8 analyses require about 10 events in each group 
before a signal would be raised (see Analysis 1, top 
of Figure 2). Among those designs, the O’Brien-
Fleming boundary threshold may be considered 
too conservative at the first analyses, requiring an 
extremely high RR of 27 or more (Figure 2, data point 
not shown) to generate a signal. This might lead a 
surveillance team to choose an 8-analysis plan with 
either the Pocock threshold (which would signal if 
the RR is about 4 at the first analysis) or a threshold 
in between these two extremes (which would require 
a RR of about 8 to signal at the first analysis).
This ACE inhibitors and angioedema example 
illustrates the type of statistical information that 
could be used to communicate the operating 
characteristics of different sequential designs 
to those designing and interpreting the safety 
surveillance activity prior to surveillance 
implementation. And, in an oversimplified way, 
it shows how such information could be used to 
compare the performance of competing designs, 
and to facilitate a dialogue among those designing 
and interpreting the safety surveillance activity 
about their design preferences. And the use of 
such information could lead to more informed final 
decisions about the choice of appropriate signaling 
thresholds. Clearly, though, the factors that influence 
the choice of sequential design selection are more 
complicated than this illustration conveys. Numerous 
scientific, ethical, and practical considerations (e.g., 
the magnitude of the vaccine or drug’s benefit, the 
prevalence and severity of the adverse event of 
interest, etc.) should bear on this choice, and the 
relative importance of each factor may depend on 
the specific safety question of interest. Our intent 
here is not to comprehensively discuss these factors 
but rather to describe a high-level framework for 
how statistical information can be used by those 
designing and interpreting the safety surveillance 
activity—to better weigh these factors when making 
sequential design decisions.
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Notes: *Assumptions: Binary outcome: Angioedema in 30 days after exposure; Comparator group: Beta blockers; Estimated rate of outcome 
among comparator group: 3.08/10,000 person-months; Power: 90% to detect a given relative risk or risk difference.
Table 4. Maximum Sample Size for Regression Analyses by Boundary Shape
LOGISTIC REGRESSION (TO ESTIMATE A RELATIVE RISK)
MAXIMUM SAMPLE SIZES
# of 
Analyses
% of total sample 
who are ACE users RR POCOCK IN-BETWEEN O'BRIEN-FLEMING
8 25% 1.5 1,153,941 990,736 943,715
2 394,857 339,012 322,922
3 157,182 134,951 128,546
50% 1.5 865,456 743,052 707,786
2 296,143 254,259 242,191
3 117,887 101,214 96,410
16 25% 1.5 1,213,358 1,003,258 951,930
2 415,189 343,296 325,733
3 165,275 136,657 129,666
50% 1.5 910,019 752,444 713,948
2 311,392 257,472 244,300
3 123,957 102,493 97,249
LINEAR REGRESSION (TO ESTIMATE A RISK DIFFERENCE)
MAXIMUM SAMPLE SIZES
# of 
Analyses
% of total sample 
who are ACE users
RD (per 10k 
person-months) POCOCK IN-BETWEEN O'BRIEN-FLEMING
8 25% 1.5 799,360 686,304 653,731
3 199,840 171,576 163,433
6 49,960 42,894 40,859
50% 1.5 599,520 514,728 490,298
3 149,880 128,682 122,575
6 37,470 32,171 30,644
16 25% 1.5 840,519 694,978 659,422
3 210,130 173,745 164,856
6 52,533 43,437 41,214
50% 1.5 630,389 521,234 494,567
3 157,598 130,309 123,642
6 39,400 32,578 30,911
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Notes: Assumptions: Binary outcome: Angioedema in 30 days after exposure; Proportion using ACE inhibitors (versus a comparator like beta 
blockers): 25%; Estimated rate of outcome among comparator group: 3.08/10,000 person-months; Power: 90% to detect a RR=2.
Figure 1. Signaling Thresholds for a Design with Four Analyses
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Notes: Assumptions: Binary outcome: Angioedema in 30 days after exposure; Proportion using ACE inhibitors (versus a comparator like beta 
blockers): 25%;  Estimated rate of outcome among comparator group: 3.08/10,000 person-months; Power: 90% to detect a RR=2.
Figure 2. Signaling Thresholds for Designs with 8 (Top) or 16 (Bottom) Analyses
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Conclusions
Existing methods used for sequential design 
planning in randomized trials and observational 
safety surveillance assessments within the VSD 
and Mini-Sentinel provide a strong foundation 
upon which to build a more formal framework 
to plan future routine safety evaluations using 
electronic health care databases. We have 
provided recommendations on how practices from 
randomized trials can be adapted to accommodate 
the unique challenges of conducting safety 
surveillance activities in the observational setting of 
electronic health care databases, which contributes 
to an emerging literature on this topic.45-46 We have 
also illustrated ways in which existing methods from 
observational settings like the VSD and Mini-Sentinel 
could be improved—by further leveraging well-
established best practices from trial settings and 
tailoring them to meet the challenges posed by an 
electronic data environment.
This review points to three important sequential 
design steps that should be addressed during the 
planning phase for safety surveillance activities 
utilizing observational electronic health care 
databases:
1. Prespecification of the surveillance design and 
analytic plan is critical.
2. Use of existing data to inform surveillance 
planning can reduce the number of assumptions 
that need to be made at the planning phase and, 
in turn, minimize downstream changes to initial 
sequential plans.
3. Selection of a sequential design should include 
statistical evaluation and clear communication of 
the sequential design and analysis with all those 
designing and interpreting the safety surveillance 
activity so that the operating characteristics are 
well understood in advance of implementation.
In addition, due to the dynamic nature of the health 
care data sources, it is important that selected 
methods offer the ability to be flexible in their 
implementation and that investigators document 
any resulting changes to initial plans that are caused 
by unpredictable data. We hope that this work can 
spark further dialogue among regulatory scientists 
about more systematic sequential-design planning 
processes and, ultimately, that it will lead to formal 
guidance with recommended best practices that 
can be used in future safety evaluations that are 
conducted using health care database information.
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